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Genomic Nutritional Profiling: Innovation and 
Regulation in Nutrigenomics 
David Castle* 
I. INTRODUCTION 
Hippocrates advised to let food be your medicine, but he 
could not have anticipated the quagmire of ethical and legal 
issues that would arise with the advent of nutritional genomics. 
Nutrigenomics is a fast-evolving field that straddles the food-
medicine distinction in order to understand the genetic 
underpinnings of the effects of nutrient metabolism on health. 
The core idea behind this emerging field is that nutrients in our 
food interact with our genes in ways that are typically benign, 
but can also be deleterious in other circumstances.1 These 
harmful interactions are implicated in the development of major 
chronic diseases. Given that individuals have slightly different 
genetic constitutions and different diets, and given that the 
interaction generates a spectrum of outcomes, the science of 
nutrigenomics faces an enormous analytical task to identify and 
categorize nutrient-gene interactions and elucidate the 
interactions’ contribution to disease. Nevertheless, the intent is 
to provide, as soon as possible, scientifically grounded 
predictions about the consequences of nutrigenomics to the 
public. 
Like other nascent fields arising from the Human Genome 
Project, such as pharmacogenomics,2 nutrigenomics must meet 
 © 2008 David Castle. 
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 1. Ruan Elliott & Teng Jin Ong, Science, Medicine, and the Future: 
Nutritional Genomics, 324 BRIT. MED. J., 1438, 1448–39 (2002). 
 2. Pharmacogenomics is the study of the heterogeneous response to drugs 
attributable to the effects of individual genetic differences that cause variation 
in drug metabolism. See, e.g., William E. Evans & Julie A. Johnson, 
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a double burden of proof before it will become widely accepted. 
On the one hand, the field is encumbered with many questions 
about the strength of the science at this early stage in its 
development. A wide range of opinion exists about the 
predictive, let alone the descriptive, capacity of genomics science 
to support the claims of nutrigenomics.3 It is fair to say that, 
while there is general consensus in the field that nutrients and 
genes interact and may be causally implicated in the 
development of disease,4  present uncertainties in the science 
lead many researchers to guard what they say about the 
relationship between nutrigenomics and chronic disease. On the 
other hand, assuming the scientific burden of proof is met, there 
remains the constellation of issues associated with public access 
to nutrigenomic products and services. These include problems 
about regulating tests and claims made about information 
disclosed by tests, decisions about public versus private 
provision of nutrigenomics, and whether nutrigenomics is 
offered direct-to-consumer or via health care practitioners.5 
Perhaps in an ideal world all relevant scientific questions 
would be identified and answered before new products and 
services reach the public. The logic of this approach is what 
motivates the costly and lengthy clinical trials that are required 
for the development and marketing of new pharmaceuticals, for 
example. Yet despite this system, even in the case of clinical 
trials for pharmaceuticals not all relevant issues are identified 
Pharmacogenomics: The Inherited Basis for Interindividual Differences in Drug 
Response, 2 ANN. REV. GENOMICS & HUM. GENETICS 9, 9–10 (2001). 
 3. For claims about the focus and scope of nutrigenomics, see, for 
example, Jim Kaput & Raymond L. Rodriquez, Nutritional Genomics: The Next 
Frontier in the Postgenomic Era, 16 PHYSIOLOGICAL GENOMICS 166 (2004). For 
doubts about genomics supporting downstream applications, see, for example, 
Richard S. Cooper & Bruce M. Psaty, Genomics and Medicine: Distraction, 
Incremental Progress, or the Dawn of a New Age?, 138. ANNALS INTERNAL MED. 
576 (2003). For more specific concerns regarding the development of tools of 
nutrigenomic science and applications, see, for example, Lenore Arab, 
Individualized Nutritional Recommendations: Do we have the Measurements 
Needed to Assess Risk and Make Dietary Recommendations?, 63 PROC. 
NUTRITION SOC’Y 167, 169–71 (2004). 
 4. Michael Müller & Sander Kersten, Nutrigenomics: Goals and 
Strategies, 4 NATURE REVIEWS GENETICS 315, 315–19 (2003). 
 5. David Castle et al., Nutrients and Norms: Ethical Issues in Nutritional 
Genomics, in NUTRITIONAL GENOMICS: DISCOVERING THE PATH TO 
PERSONALIZED NUTRITION, 419, 422–33 (Jim Kaput & Raymond L. Rodriguez 
ed., 2006). 
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and dealt with, as the recent worldwide market withdrawal of 
Merck’s osteoarthritic drug Vioxx demonstrates.6 The situation 
with nutrigenomics is even more complicated because 
commercial products and services have been made available to 
the public for several years, but unlike pharmaceuticals, 
nutrigenomic products and services do not find their way to 
market with a system to evaluate their utility. This is not to 
recommend that nutrigenomics ought to follow a clinical trial 
protocol; it is to point out that what would count as an 
appropriate regulatory regime for nutrigenomics continues to be 
an open question. In fact, it is an evolving question, one whose 
parameters are not fixed and cannot be, for at least three 
reasons. First, the science is rapidly changing, which means 
that regulators must evaluate a field whose scope, exemplars 
and evidentiary base are constantly changing. Second, because 
nutrigenomics is already available to the public, regulators 
must contend with the fact that the private sector is adapting 
quickly to competition and to market signals. Third, in light of 
the evolution of the science and commercial developments, 
regulators must cope with the problem of fitting existing 
regulations and regulatory practices to nutrigenomics even 
though these regulations existed prior to the advent of this field. 
This paper argues that nutrigenomics regulation cannot be 
achieved by simply identifying potential hazards and then 
regulating proportionately to those harms. Instead, 
nutrigenomics presents an on-going regulatory challenge 
because the field as a whole is genuinely innovative, meaning 
that existing regulations and regulatory approaches lack built-
in capacity for the new field. While this may seem like an 
obvious claim in light of the controversy surrounding 
nutrigenomics regulation, the reasons for it, and implications to 
be drawn, are somewhat more subtle. To begin with, clarity 
about the status of the science must be reached before claims 
about regulatory deficiencies can be addressed. Regulatory gaps 
can take the form of instances where identified hazards call for 
new regulations, but the more important point is that the 
evaluation of nutrigenomics discloses a persistent problem in 
regulatory systems where food and nutrition are regulated 
separately from medicine and drugs.7 Nutrigenomics is an 
 6. Richard Horton, Vioxx, the Implosion of Merck, and Aftershocks at the 
FDA, 364 LANCET 1995, 1995 (2004). 
 7. In the United States, the Food and Drug Administration (FDA) 
regulates foods and drugs under the same act, Federal Food, Drug, and 
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innovative field in which much of the novelty lies in a deliberate 
convergence between the traditionally separated fields of food 
and medical regulation. The important implication arising from 
the development of this thesis is that regulators will not find a 
simple, elegant solution to the regulation of nutrigenomics so 
long as they attempt to retrofit existing food and drug 
regulations to a fast moving, innovative field. An important 
indicator is the use of non-statutory tools for regulations, such 
as guidance documents, which are on the rise in the attempt to 
keep pace with nutrigenomics. 
II. HUMAN GENETICS AND NUTRIGENOMICS 
If the Human Genome Project is considered in light of the 
time it took for the human genome to evolve, it is a very recent 
event. Yet for those who have invested their careers in the 
Project since its inception in 1990 and before, it seems quite 
long. Many are impatient to see the fruits of the multi-billion 
investment of public and private funds, and lament that the 
“sequencing of the human genome, once thought to be the key to 
unlocking the discovery of common genetic contributors to 
cancer, heart disease, diabetes and other complex disease, has 
turned out to be only a first step along a much longer path.”8 
Perhaps one day, human genetics will become a routine part of 
the medical practice, an aspiration that was certainly part of the 
motivation for early release of the draft sequences once they 
were completed in 2001.9 Part of the problem in translating the 
Project into application is that the early estimates of the 
number of human genes—sometimes ranging as high as 
Cosmetic Act, 21 U.S.C. §§ 301–399 (2000), but the regulation of foods and 
drugs are carried out under different sections of the Act and under separate 
authority of the Administration. See OFFICE OF MGMT. PROGRAMS, FDA 
ORGANIZATION CHART (2007), available at http://www.fda.gov/oc/orgcharts/ 
FDA.pdf. The situation is similar in Canada, where Health Canada is the 
regulatory authority, but treats food and drugs separately under the Food and 
Drugs Act, R.S.C., ch. F-27 (1985). See Heatlth Canada: Branches and 
Agencies, http://www.hc-sc.gc.ca/ahc-asc/branch-dirgen/index_e.html (last 
visited Feb. 28, 2008). 
 8. M.W. Foster et al., The Routinisation of Genomics and Genetics: 
Implications for Ethical Practices, 32 J. MED. ETHICS 635, 635 (2006). 
 9. See J. Craig Venter et al., The Sequence of the Human Genome, 291 
SCIENCE 1304, 1305 (2001); Int’l Human Genome Sequencing Consortium, 
Initial Sequencing and Analysis of the Human Genome, 409 NATURE 860, 862–
63 (2001). 
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120,000—fell dramatically to about 30,000.10 This has meant 
that the idea of a central dogma in which one gene would 
produce one structural or functional protein gave way to a one-
to-many problem in which the multiple roles of genes must now 
be elucidated. Compounding the problem is that of the three 
billion base pairs in each human genome, there is an inborn 
error rate of approximately one in every one thousand base 
pairs being a substitute for the correct version. This error rate 
gives rise to at least three million, possibly as many as 10 
million, single nucleotide polymorphisms (SNPs). SNPs are 
structural variations in a genome which give rise to functional 
variations in gene products or in the regulation of genes.11 With 
fewer genes, but more common built-in errors, the science of 
functional genomics is much more complicated. 
To further complicate matters, in the course of the Human 
Genome Project it has become apparent that genes neither give 
rise to their products nor regulate their activity isolated from 
their environment. Environmental exposure to drugs,12 toxins13 
and nutrients have quickly become of great interest to those 
wishing to understand functional genetics in light of systems 
biology.14 Gene-environment interaction “refers to the 
differential phenotypic effects of diverse environments on 
individuals with the same genotype or to the discrepant effects 
of the same environment on individuals with different 
genotypes.”15 Twin studies are often used to illustrate this point 
since genetically identical twins interact with dissimilar 
environments with different outcomes, in fact, a journal 
 10. Venter et al., supra note 9; Int’l Human Genome Sequencing 
Consortium, supra note 9. 
 11. The International HapMap Project, which evolved out of the SNP 
Consortium, is dedicated to cataloguing SNPs and to devising improved 
methods for detecting human genetic variation. See INT’L HAPMAP PROJECT, 
ABOUT THE HAPMAP, http://snp.cshl.org/thehapmap.html.en (last visited Feb. 
28, 2008). 
 12. See, e.g., Werner Kalow, Historical Aspects of Pharmacogenetics, in 
PHARMACOGENOMICS 1, 4 (Werner Kalow et al. eds., 2nd ed. 2005). 
 13. See, e.g., Charles W. Schmidt, Toxicogenomics: An Emerging Discipline, 
110 ENVTL. HEALTH PERSP. 750, 750–52 (2002). 
 14. See, e.g., Leroy Hood, Systems Biology: Integrating Technology, Biology, 
and Computation, 124 MECHANISMS  AGEING & DEV. 9, 13 (2003); Ben van 
Ommen, Nutrigenomics: Exploiting Systems Biology in the Nutrition and 
Health Arenas, 20 NUTRITION 4, 4–7 (2004). 
 15. Dolores Corella et al., APOA5 Gene Variation modulates the Effects of 
Dietary Fat Intake on Body Mass Index and Obesity Risk in the Framingham 
Heart Study, 85 J. MOLECULAR MED. 119, 120 (2007). 
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dedicated to twin research and human genetics exists.16 Twins 
represent a kind of controlled natural experiment, but they are 
the exception. The reality is much more like the difference 
between Winston Churchill, who famously enjoyed his drink and 
cigars and lived to the age of 90, and James Fixx, author of the 
Complete Book of Running,17 who nevertheless met an early 
death at the age of 52. 
Nutrigenomics investigates the interaction between 
nutrients and genes. Genes affect how nutrients are 
metabolized, and reciprocally, nutrients affect how genes are 
expressed and regulated.18 The goals of nutrigenomics are thus 
two-fold.19 On the one hand, the goal is to understand the 
functional interaction between bioactive food components with 
the genome at the molecular, cellular and systemic level.20 The 
goal is to understand the role of nutrients in gene expression, 
generally speaking, and more importantly how diet can be used 
to prevent or treat disease. On the other hand, if one takes into 
account the phenomenon of human genetic variation, the second 
goal of nutrigenomics is to understand the effect of genetic 
variation on the interaction between diet and disease.21 In this 
respect, the focus is on an individual’s specific response to food 
due to genetic variants or polymorphisms in order to develop 
dietary recommendations regarding the risks and benefits of 
specific diets or dietary components to individuals as well as 
populations.22 
 16. A recent example concerning food choice is Birgit Teucher et al., 
Dietary Patterns and Heritability of Food Choice in a UK Female Twin Cohort, 
10 TWIN RES. & HUM. GENETICS 734 (2007). While it is tempting to think that 
twin studies point definitively to the contribution of environmental factors to 
development, it is often difficult to clearly identify causal factors from 
confounding events. On this issue see, for example, Eric Turkheimer et al., 
Analysis and Interpretation of Twin Studies Including Measures of the Shared 
Environment, 76 CHILD DEV. 1217 (2005). 
 17. JAMES FIXX, THE COMPLETE BOOK OF RUNNING (1977). 
 18. See, e.g., Evans & Johnson, supra note 2, at 11–14. 
 19. See, e.g., Dolores Corella & Jose M. Ordovas, Single Nucleotide 
Polymorphisms that Influence Lipid Metabolism: Interaction with Dietary 
Factors, 25 ANN. REV. NUTRITION 341, 353 (2005). 
 20. See Artemis P. Simopoulos, Genetic Variation and Dietary Response: 
Nutrigenetics/Nutrigenomics, 11 ASIA PAC. J. CLINICAL NUTRITION S117, S117 
(2002). 
 21. Id. 
 22. DAVID CASTLE ET AL., SCIENCE, SOCIETY AND THE SUPERMARKET: THE 
OPPORTUNITIES AND CHALLENGES OF NUTRIGENOMICS 10–12, 22–33 (2007). 
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An example of nutrigenomics involves the relationship 
between caffeine intake from beverages like coffee, tea and soft 
drinks and a gene for an enzyme, cytochrome P450 1A2.23 There 
are known variants of the gene, CYP1A2, which come in two 
forms: the CYP1A2*1A variant which is associated with rapid 
caffeine metabolism, and the CYP1A2*1F variant, which is 
associated with slow caffeine metabolism.24 In the study 
conducted by Cornelis and her colleagues, 2014 people had their 
CYP1A2 genes sequenced, of which slightly more than half 
(1114) had the variant associated with slower caffeine 
metabolism.25 While controlling for caffeine consumption, a 
slightly higher incidence of non-fatal myocardial infarctions was 
reported for the group of coffee drinkers who were slow 
metabolizers as compared to those who were fast metabolizers of 
caffeine.26 The conclusion is that there is an association between 
having the CYP1A2*1F variant, caffeine consumption, and non-
fatal myocardial infarction, whereas having the CYP1A2*1A 
might confer a relative protective effect because caffeine is 
metabolized up to four times as quickly.27 
Another example of nutrigenomics concerns lipid 
metabolism. Using participants from the Framingham Offspring 
Study, Corella and Ordovas studied the relationships between 
variants of the APOA5 gene, lipid metabolism, and body-mass 
index (BMI).28 The APOA5 gene has several known SNPs, of 
which the 1131T>C is in linkage disequilibrium, which is to say 
the alleles occur in non-random patterns, and the 56C>G is 
not.29 In their study, presence or absence of the 56C>G SNP had 
no discernable impact on the relationship between BMI and the 
total caloric intake attributable to lipid.30 That is, irrespective of 
genotype, the phenotype associated with higher percentage of 
caloric intake attributable to lipids was always the same—
higher BMI. The same was not true with 1131T>C variants.31 
The majority has the TT variant, and shows a standard dose 
 23. Marilyn C. Cornelis et al., Coffee, CYP1A2 Genotype, and Risk of 
Myocardial Infarction, 295 JAMA 1135, 1135 (2006). 
 24. Id. 
 25. Id. at 1136. 
 26. Id. at 1136–38. 
 27. Id. at 1138–40. 
 28. Corella & Ordovas, supra note 19, at 348–55. 
 29. PHILIP W. HEDRICK, GENETICS OF POPULATIONS 525–40 (3rd ed. 2005). 
 30. Corella & Ordovas, supra note 19, at 350–52. 
 31. Id. at 378–79. 
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response to increasing the proportion of calories attributable to 
lipids.32 As the participants increase lipid intake as a 
percentage of calories consumed, their BMI goes up.33 Yet for 
the 13% of the study group that has the CT variant, the opposite 
effect is observed.34 For men and women in this group, the T>C 
variant has a protective effect against increased BMI, 
particularly when the composition of lipids is weighted toward 
mono unsaturated fatty acids (MUFAs).35 
These examples are typical of the kind of nutrient-gene 
association studies that comprise most studies in nutrigenomics. 
In these studies, a gene with known variants is identified 
because it has known or suspected significance in a metabolic 
pathway, and because the variants occur in non-trivial numbers 
in the population. The method is designed to establish a 
statistically significant correlation between the variant, one or 
more nutrients, and a measurable outcome, such as increased 
risk of non-fatal myocardial infarction or increased body-mass 
index. 
Another approach to nutrigenomics is to examine trends in 
phenotypes that happen in ostensibly distinct populations of 
people, and to try to clarify the underlying gene-nutrient 
cause.36 For example, most non-Europeans have some level of 
lactose intolerance because they have two polymorphisms that 
lack the enzyme, lactase, necessary to break down this milk 
sugar.37 Similarly, Asian populations generally have low levels 
of alcohol dehydrogenase, the enzyme necessary to break down 
alcohol.38 African American populations have higher than 
average levels of hypertension, attributable to the different 
activity angiotensinogen, an α-2 globulin protein released 
 32. Id. 
 33. Id. 
 34. Id. 
 35. Id. at 358–62. 
 36. See generally Richard S. Spielman et al., Common Genetic Variants 
Account for Differences in Gene Expression Among Ethnic Groups, 39 NATURE 
GENETICS 226 (2007). 
 37. Todd Bersaglieri et al., Genetic Signatures of Strong Recent Positive 
Selection at the Lactase Gene, 74 AM. J. HUM. GENETICS 1111, 1111–12 (2004); 
see also Sarah A. Tishkoff et al., Convergent Adaptation of Human Lactase 
Persistence in Africa and Europe, 39 NATURE GENETICS 31, 32–34 (2007). 
 38. H.W. Goedde et al., Distribution of ADH2 and ALDH2 Genotypes in 
Different Populations, 88 HUM. GENETICS 344, 345–46 (1992). 
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largely by the liver.39 Some, but not all people are able to taste 
bitterness, and to varying degrees as a result of activity of the 
taste receptor gene TASR.40 
The hope of being able to develop public health measures 
for genetically identified groups is a powerful motivation for 
studying the genetics of populations. The scientific difficulty lies 
in being able to use genetics to draw definitive lines between 
“races” or “ethnicities.” Geneticists have long known that within 
populations there can be a great deal of intra-group variation, in 
fact, statistically speaking there can be greater intra-group 
variation compared to inter-group variation.41  Ioannidis et al. 
conducted a study in which they examined forty-three disease-
gene associations in 697 study populations in search of “racial” 
differences that would underlie complex diseases.42 They found 
that genetic variants do exist within populations, but they were 
unable to conclude that these made significant contributions to 
disease progression attributable to “races” or “ethnicities.”43 Yet 
at the same time there are well-known situations that suggest 
that searching for these differences in populations is not a 
pointless undertaking. Pima Indians in the United States have 
nearly twenty times higher incidence of type II diabetes 
compared with the rest of the U.S. population.44 This high 
incidence is partially attributable to their diet, for their 
counterparts in Mexico who consume a more traditional diet, as 
well as evidence drawn from the historical record, suggests that 
Pima Indians have no higher background rates of type II 
diabetes when they consume their traditional diet.45 Yet 
changes to dietary patterns do not explain why their incidence 
 39. Richard S. Cooper et al., Heritability of Angiotensin-Converting Enzyme 
and Angiotensinogen: A Comparison of US Blacks and Nigerians, 35 
HYPERTENSION 1141, 1144–45 (2000). 
 40. Dennis Drayna, Human Taste Genetics, 6 ANN. REV. GENOMICS & HUM. 
GENETICS 217, 218–20 (2005). 
 41. See generally, Richard C. Lewontin, The Appointment of Human 
Diversity, 6 EVOLUTIONARY BIOLOGY 381 (1972); Noah A. Rosenberg et al., 
Genetic Structure of Human Populations, 298 SCIENCE 2381 (2002). 
 42. John P.A. Ioannidis et al., ‘Racial’ Difference in Genetic Effects for 
Complex Diseases, 36 NATURE GENETICS 1312 (2004). 
 43. Id. at 1315–16. 
 44. William C. Knowler et al., Diabetes Incidence and Prevalence in Pima 
Indians: A 19-Fold Greater Incidence than in Rochester, Minnesota, 108 AM. J. 
EPIDEMIOLOGY 497, 498–99 (1978). 
 45. V.L. Boyce & B.A. Swinburn, The Traditional Pima Indian Diet. 
Composition and Adaptation for Use in a Dietary Intervention Study, 16 
DIABETES CARE 369, 369–70 (1993). 
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of diabetes is drastically higher than the rest of the U.S. 
population. A genetic basis shared by the Pima for this uniquely 
detrimental dietary response is a reasonable hypothesis. 
III. SOURCES OF CONTROVERSY: PUBLIC ACCESS TO 
NUTRITIONAL GENOMICS 
Nutrigenomics research is being undertaken to accomplish 
the twin goals of generating a genomic science of nutrient-gene 
interaction as well as a science of personal genetics and diet. 
Obviously, these must work in concert to have a complete 
science working from general principles translated to practical 
applications.46 Although there is no disputing that 
environmental influences on genomes are causes of differential 
gene expression and regulation, and equally there is no doubt 
that nutrients can have these effects on genes, there is 
disagreement about the conclusions one can draw from nutrient-
gene associations, particularly with respect to implications for 
disease etiology and progression. The concerns that have been 
voiced tend to fall along three lines: the view that the basic 
science has not matured to the point where it can be translated 
into applications;47 the view that the public provision of 
nutrigenomics is premature;48 and the view that nutrigenomics 
targeted at populations is premature and problematic because 
not enough is known about disease susceptibility genes.49 Each 
of these will be considered in turn. 
Optimism for the theory behind nutrigenomics can be 
distinguished from positive views about the extent to which the 
science can be applied, particularly in the form of 
commercialized products and services. In this respect, 
nutrigenomics gets swept up in a general claim about the 
prematurity of translating any genomic science into publicly 
available applications. In their widely read and influential 
paper, Susanne Haga, Muin Khoury and Wylie Burke argued 
that using genomics to develop individual risk profiles is “not 
 46. CASTLE ET AL., supra note 22, at 8–12, 33–42; Simopoulos, supra note 
20. 
 47. Arab, supra note 3, at 169–70. 
 48. Susanne B. Haga et al., Genomic Profiling to Promote a Healthy 
Lifestyle: Not Ready for Prime Time, 34 NATURE GENETICS 347, 348–49 (2003). 
 49. Kathleen Ries Merikangas & Neil Risch, Genomic Priorities and Public 
Health, 302 SCIENCE 599, 599–600 (2003). 
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ready for primetime.”50 They contend that even if one could 
come up with reliable genetic profiles for individuals, 
translating them into clinically valid and clinically useful 
applications is in the future.51 What they have in mind is 
“personalized nutrition,” in which individual are tested for a 
panel of genes and given dietary advice depending on which 
SNPs are identified.52 They focus on methylenetretrahydrofolate 
reductase (MTHFR), which is an often cited example of 
nutrigenomics.53 A well-characterized polymorphism, 677C>T 
leads to lower activity of the enzyme, which lowers the 
conversion of homocysteine to methionine.54 Increased blood 
levels of homocysteine is considered a cardiovascular disease 
risk factor. While the nutrient-gene interaction is well 
characterized,55 there is dispute in the literature about whether 
dietary supplementation with folate really does lower the risk of 
cardiovascular disease.56 Part of the problem is that the 
frequency for the 677C>T polymorphism is estimated at 10–
15%, making it difficult to follow its effects outside of studies 
with large samples.57 Furthermore, cohort and intervention 
studies need to be conducted to show, in controlled conditions, 
the effect of folate supplementation.  
As Ordovas and Corella have pointed out in their 2004 
review of nutrigenomics, MTHFR exemplifies many of the gaps 
in knowledge in nutrigenomics: lack of knowledge of all system 
components; the need to improve experimental design, dietary 
assessments and statistics; and the tools to study and visualize 
complex interaction with the support of massive computing 
power.58 One day nutrigenomics might be able to support the 
 50. Haga et al., supra note 48, at 347. 
 51. Id. at 348–49. 
 52. Id. 
 53. Peter J. Gillies, Nutrigenomics: The Rubicon of Molecular Nutrition, 
103 J. AM. DIETETIC ASS’N (SUPPLEMENT 2) S50, S52 (2003). 
 54. Raymond Meleady et al., Thermolabile Methylenetetrahydrofolate 
Reductase, Homocysteine, and Cardiovascular Disease Risk: The European 
Concerted Action Project, 77 AM. J. CLINICAL NUTRITION 63, 63 (2003). 
 55. Pauline A.L. Ashfield-Watt et al., Methylenetetrahydrofolate Reductase 
677C→T Genotype Modulates Homocysteine Responses to a Folate-Rich Diet or 
a Low-Dose Folic Acid Supplement: A Randomized Controlled Trial, 76 AM. J. 
CLINICAL NUTRITION 180, 181 (2002). 
 56. Lydia A. Bazzano et al., Effect of Folic Acid Supplementation on Risk of 
Cardiovascular Diseases, 296 JAMA 2720, 2721, 2723–25 (2006). 
 57. The Homocysteine Studies Collaboration, Homocysteine and Risk of 
Ischemic Heart Disease and Stroke, 288 JAMA 2015, 2021 (2002). 
 58. Jose M. Ordovas & Dolores Corella, Nutritional Genomics, 5 ANN. REV. 
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nutritional preemption of disease, but it will have to overcome 
complex obstacles of integrating basic science with practical 
applications and service delivery.59 
The lightening rod of nutrigenomics has been directly 
providing nutrigenomic tests to consumers (i.e. consumers are 
able to buy over-the-counter, at-home genetic tests). The issue 
began shortly after the 2001 formation of Sciona, a private 
company in the United Kingdom, which began offering 
nutrigenomic tests directly to consumers through retail outlets. 
Sciona was soon embroiled in a controversy started by the non-
governmental organization and genetics watchdog GeneWatch 
and the U.K. Consumers Association, operating under the trade 
name “Which?”60 These organizations were concerned with the 
potential to mislead consumers and mistreat genetic data. Soon, 
the Guardian, a U.K. daily newspaper took up the issue, and the 
Human Genetics Commission, a governmental advisory body, 
began its review of direct-to-consumer genetic tests.61 Part of 
the problem stemmed from the novelty of nutrigenomics itself, 
which raised legitimate questions, discussed above, about the 
quality of the science that was being translated into 
applications, but there are more fundamental concerns about 
the quality of the tests themselves62 and the enforceability of 
the few regulations that applied
More recently, the Government Accountability Office (GAO) 
in the United States “ghost shopped” several nutrigenomics 
firms using fourteen fictitious personae in order to evaluate the 
GENOMICS & HUM. GENETICS 71, 102–03, 106–07 (2004). 
 59. See Peter J. Gillies & Elaine S. Krul, Using Genetic Variation to 
Optimize Nutritional Preemption, 137 J. NUTRITION 270S, 271S–73S (2007). 
 60. James Meek, Public ‘Misled by Gene Test Hype:’ Scientists Cast Doubt 
on ‘Irresponsible’ Claims for Checks Offered by Body Shop, GUARDIAN (U.K.), 
Mar. 12, 2002, at 9; Press Release, GeneWatch UK, Leaked Document Exposes 
Government Failure to Regulate Human Genetic Tests (June 4, 2002), 
available at http://www.genewatch.org/article.shtml?als[cid]=492860&als 
[itemid]=504430; see generally Which? Home Page, http://www.which.co.uk 
(last visited Feb. 21, 2008). 
 61. HUMAN GENETICS COMM’N, GENES DIRECT: ENSURING THE EFFECTIVE 
OVERSIGHT OF GENETIC TESTS SUPPLIED DIRECTLY TO THE PUBLIC (2003), 
available at http://www.hgc.gov.uk/UploadDocs/DocPub/Document/ 
genesdirect_full.pdf . 
 62. Marcus Stevenson, Good Gene Hunting: Commercializing Safety and 
Efficacy of Home Genetic Test Kits, 3 J. BIOLAW & BUS. 29, 30–38 (1999). 
 63. James Meek, Genetic Testing Rules ‘Unenforceable:’ Watchdog Calls for 
Suspension of Unusable Code of Practice, GUARDIAN (U.K.), June 4, 2002, at 7. 
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genetic tests, the assessments of the nutrigenomics profile, and 
the linkages between nutrigenomics testing services and the 
sale of dietary supplements.64 The GAO secretly paid for 
services of nutrigenomics companies, sending fictitious personal 
and lifestyle information to several companies.65 The GAO 
reported inconsistencies in the results, questioned the methods 
of the firms, and challenged the veracity and utility of the 
claims provided by the companies.66 Although there are several 
methodological flaws in the report, the conclusion that at-home 
genetic tests offered to consumers are snake-oil was uncritically 
repeated.67 The flaws in the methodology and conclusions of the 
GAO report are serious and potentially damaging to private 
interests in nutrigenomics, as well as public confidence in the 
Food and Drug Administration (FDA).  There is, however, an 
equal claim that the direct-to-consumer market is not immune 
from criticism. As we shall see below, the net effect, intended or 
not, is that the FDA must now take steps to address the real 
and perceived regulatory lacunae falling within its mandate. As 
with the Human Genetics Commission in the United Kingdom, 
this is not merely a matter of inter-mural jostling between parts 
of government, aided and abetted by non-governmental 
organizations. 
There are concerns about direct-to-consumer genetic tests 
garnering media attention where they may shape the public’s 
perception of nutrigenomics.68 Unfortunately, very little 
information of consumer awareness, attitudes and intent to 
purchase nutrigenomics products and services is available. The 
Institute for the Future in California has conducted research for 
its members on the potential for nutrigenomics market 
development,69 but social science research from an academic 
 64. U. S. GOV’T ACCOUNTABILITY OFFICE, REPORT NO. GAO-06-977T, 
NUTRIGENETIC TESTING: TESTS PURCHASED FROM FOUR WEB SITES MISLEAD 
CONSUMERS (2006). 
 65. Id. 
 66. Id. 
 67. Gene Russo, Home Health Tests are ‘Genetic Horoscopes,’ 442 NATURE 
497, 497 (2006); Andrew Pollack, The Wide, Wild World of Genetic Testing, N.Y. 
TIMES, Sept. 12, 2006, at G4; Unmesh Kher, Can a DNA Test Tell You How to 
Live Your Life?, TIME, Aug. 1, 2006, http://www.time.com/time/nation/ 
article/0,8599,1221727,00.html. 
 68. INT’L FOOD INFO. COUNCIL, 2005 CONSUMER ATTITUDES TOWARD 
FUNCTIONAL FOODS/FOODS FOR HEALTH 12–13 (2006). 
 69. MARY CAIN & GREG SCHMID, INST. FOR THE FUTURE, FROM 
NUTRIGENOMIC SCIENCE TO PERSONALIZED NUTRITION: THE MARKET IN 2010, 
at 45–60 (2003). 
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setting lags behind. 
In light of the concerns regarding the readiness of the 
science for translation into practice and direct-to-consumer 
provision of nutrigenomic tests, population-level applications 
which would target genetic sub-populations using race as a 
proxy for genetic variation might seem more appealing than 
targeting individual genetic differences. Two different 
approaches to population-level nutrigenomics exist. One is the 
development of a research platform that seeks to understand 
the causes of health disparities between groups, for instance 
The National Center on Minority Health and Health Disparities 
Center for Excellence for Nutritional Genomics at the 
University of California, Davis which has as its mission “to 
reduce and ultimately eliminate racial and ethnic health 
disparities resulting from environment x gene interactions, 
particularly those involving dietary, economic and cultural 
factors.”70 The private sector has a similar interest in 
populations. For example, the company Interleukin Genetics 
has interest in targeted marketing for osteoporosis tests because 
they believe that the COL1A1 SNP test can differentiate 
osteoporosis risk in Caucasians and Asians.71 Yet it is precisely 
this research and these applications of genetics that attract 
criticism from those who are concerned about the integration of 
unwarranted racial profiling in research and market 
development.72 Part of the concern is the error-prone misuse of 
race as a proxy for genetic variation, the other part is the 
perpetuation of racial stereotypes that neither fit social nor 
biological realities. The fear is that genetics could repeat the ills 
of the past by becoming a new eugenics,73 or eugenomics,74 in 
 70. National Center for Minority Health and Health Disparities (NCMHD) 
Center of Excellence for Nutritional Genomics Home Page, 
http://nutrigenomics.ucdavis.edu/nutrigenomics/ (last visited Feb. 21, 2008). 
 71. Press Release, Interleukin Genetics, Interleukin Genetics Initiates 
Study of IL-1 Gene Variation and Osteoporosis in Korean Women (Sept. 7, 
2006), available at http://ilgenetics.com/content/about-interleukin/newsDetail. 
jsp/q/news-id/93. 
 72. Sandra Soo-Jin Lee, Racializing Drug Design: Implications of 
Pharmacogenomics for Health Disparities, 95 AM. J. PUB. HEALTH 2133, 2137–
37 (2005). 
 73. Garland E. Allen, Is a New Eugenics Afoot?, 294 SCIENCE 59, 59–60 
(2001). 
 74. Julie M. Aultman,  Eugenomics: Eugenics and the Ethics in the 21st 
Century, 2 GENOMICS, SOC’Y & POL’Y 28, 44–46 (2006). 
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which science and technology are channeled in the direction of 
replacement or augmentation of traits, rather than disease 
prevention and therapy. One study, however, finds no direct 
evidence of states directly coercing their population to undergo 
genetic testing—which if true speaks directly against the 
concerns just described in which eugenics features as a state-
supported campaign against unwanted genetic variation. As the 
authors of the study say, people do not appear to be “regulated, 
sanctioned and manipulated by others who press them to 
comply with public health objectives.”75 But it may be that what 
people “conceive as rational, morally binding and desirable, 
reproduces collective imperatives and social control.”76 That is, 
individual adoption of eugenics or eugenomics is a more 
seditious reality because groups can be manipulated to create, 
or replicate, messages not necessarily of their own making. 
IV. NUTRIGENOMICS INNOVATION: AN EXAMPLE OF 
CONVERGENT TECHNOLOGIES 
Nutrigenomics is a highly innovative field in which new 
science and technology is being generated, creating opportunity 
to develop innovative regulatory responses. Nutrigenomics 
explores novel environmental genomics linkages between 
nutrients and genes.  These associations create the potential for 
individual, group and public health interventions. At the same 
time, nutrigenomics raises many intriguing issues about 
establishing regulatory environments which address the legal 
and ethical dimensions of the field.77 Among these: the need to 
address the collection and storage of biological samples and 
genetic data, privacy issues, distributive justice issues about 
access, and models of service delivery.78 Practical issues also 
extend to considerations about the necessary training and 
development of competency in health care professions who must 
respond to public demand for services and advice.79 
 75. Wolfgang van den Daele, The Spectre of Coercion: Is Public Health 
Genetics the Route to Policies of Enforced Disease Prevention?, 9 COMMUNITY 
GENETICS 40, 41 (2006). 
 76. Id. 
 77. Nola M. Ries & Timothy Caulfield, First Pharmacogenomics, Next 
Nutrigenomics: Genohype or Genohealthy?, 46 JURIMETRICS J. 281, 285–300, 
302–04 (2006). 
 78. Castle et al., supra note 5. 
 79. David Castle & Nola M. Ries, Ethical, Legal and Social Issues in 
Nutrigenomics: The Challenges of Regulating Service Delivery and Building 
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Discussions of ethical and legal issues raised by 
nutrigenomics focus on regulatory systems’ capacity to adapt 
existing regulations to unanticipated applications arising from 
nutrigenomics because some perceive the field as entirely 
unregulated.80 In general, this is a sensible approach to 
practical problems in identifying and filling in regulatory gaps 
arising from new science and technology.  Further attention 
devoted to the system of innovation that gives rise to 
nutrigenomics facilitates and enhances success in tackling the 
practical regulatory issues.  Nutrigenomics is the product of 
several decades of advances in molecular nutrition science,81 
leveraged by comparatively more recent human genomics and 
genetics.82 Whereas nutrition science has tended to reside more 
on the side of human physiology and biochemistry than within 
the context of medicine, the distinctly biomedical framework of 
the Human Genome Project has permanently changed the 
course of nutrition science in the direction of biomedicine. The 
role of genomics as an environmental determinant of health has 
further broadened nutrition science to include the social and 
environmental sciences in a more expansive and evolving 
conception of the field.83 
Whereas some fields of science and technology tend to stay 
within rather narrowly prescribed boundaries, changes in 
nutrition science, particularly because of the advent of 
nutrigenomics, cross over those boundaries. It is useful to 
distinguish between conventional and convergent science and 
technology.84 Conventional science and technology tends to be 
bounded by the subject matter or methods employed in the 
science—embryology is a common example drawn from the 
history of science. Convergence in science and technology 
happens when fields that might otherwise be regarded as 
conventional are overlapped to leverage new opportunities to 
ask different kinds of questions and to use blends of scientific 
methodologies. Among the more obvious recent examples are 
Health Professional Capacity, 622 MUTATION RES. 138, 141–42 (2007). 
 80. Id. 
 81. Ordovas & Corella, supra note 58, at 71–73. 
 82. Müller & Kersten, supra note 4, at 315–16. 
 83. See Geoffrey Cannon & Claus Leitzmann, The New Nutrition Science 
Project, 8 PUB. HEALTH NUTRITION 673, 679–82, 687–91 (2005). 
 84. DAVID CASTLE ET AL., CONVERGENCE IN BIOTECHNOLOGY INNOVATION: 
CASE STUDIES AND IMPLICATIONS FOR REGULATION 24–28 (2006). 
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nanoscience and nanotechnology, particularly as these areas 
drive convergence between information technology, 
biotechnology and cognitive science.85 As with nanoscience and 
nanotechnology, there is interest in the development of new 
technologies destined to be marketable products and services, as 
well as the development of enabling scientific platforms based 
on technological advances that will further enable research and 
development.86 Predictably, there is uptake on the issue about 
whether the commercial science and technology are moving too 
quickly in advance of regulatory science and public acceptance.87 
Innovation in convergent science and technology has an 
impact on regulation because it exposes the limitations of 
existing regulations to cope with new products and services. A 
case in point is the regulation of direct-to-consumer genetic 
tests. In other situations, convergent science and technology join 
disparate fields of science and technology, but the regulations 
for the conventional fields may not also converge, creating gaps 
in regulation. Concerns about the regulation of plant-made 
products, for instance, often focus on regulatory gaps.88 In a 
third case, convergent science and technology raises the 
potential for new hazards requiring identification, 
characterization, and the development of regulations 
proportionate to the risk posed by the new science and 
technology. Nanoscience and nanotechnology find themselves in 
this exact situation; the challenge is for regulatory science to 
develop scientific tools that will enable regulators to precisely 
define and respond to regulatory issues.89 
 85. See, e.g., CONVERGING TECHNOLOGIES FOR IMPROVING HUMAN 
PERFORMANCE: NANOTECHNOLOGY, BIOTECHNOLOGY, INFORMATION 
TECHNOLOGY AND COGNITIVE SCIENCE (Mihail C. Roco & William Sims 
Bainbridge eds., 2003). 
 86. See, e.g., GILL RINGLAND ET AL., NEW TECHNOLOGY WAVE: 
TRANSFORMATIONAL EFFECT OF NBIC TECHNOLOGIES ON THE ECONOMY 5–6, 
8–12, 17–19, 24 (2004), available at http://ec.europa.eu/research/conferences/ 
2004/ntw/pdf/sig3_en.pdf. 
 87. See, e.g., M.C. Roco, Broader Societal Issues of Nanotechnology, 5 J. 
NANOPARTICLE RES. 181, 184–86 (2003); WORLD COMMISSION ON THE ETHICS 
OF SCIENTIFIC KNOWLEDGE AND TECHNOLOGY (COMEST), 
NANOTECHNOLOGIES AND ETHICS: POLICIES AND ACTIONS 8–10 (2007). 
 88. Julian K-C. Ma et al., Molecular Farming for New Drugs and Vaccines: 
Current Perspectives on the Production of Pharmaceuticals in Transgenic 
Plants, 6 EUR. MOLECULAR BIOLOGY ORG. REP. 593, 595–97 (2005). 
 89. See Michael D. Mehta, From Biotechnology to Nanotechnology: What 
Can We Learn from Earlier Technologies?, 24 BULL. SCI., TECH. & SOC’Y 34, 35–
37 (2004). 
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The convergence of genomics and genetics with nutrition 
science raises generic issues for regulators, but of course the 
urgency and severity of the problem varies considerably among 
jurisdictions. In general, it is safe to say that as more is known 
about the bioactivity of food components, with or without the 
augmentation of genetic profiling, the regulation of functional 
foods, nutraceuticals and supplements will encroach upon drug 
regulations.90 Regulatory gaps can appear if foods with high 
bioactivity, or derivatives thereof, are not regulated and thus 
fall through domains of regulatory scrutiny. Nutrigenomic tests 
present other challenges for regulators who must decide if 
products and services offered are along the spectrum of life-style 
tests, disease susceptibility tests, or constitute tests that 
deserve more advanced regulatory control as they would if 
regulated as a medical device. Regulators might also consider 
whether the clinical validity and utility of nutrigenomic tests 
requires regulatory oversight. Access to the tests and the 
information they generate is also a major regulatory issue if it is 
believed that nutrigenomic tests ought to conform to a high level 
of patient consent, rather than caveat emptor for clients, and 
whether strict controls on testing children ought to be enforced. 
In general, nutrigenomics creates uncertainty for regulators 
because it is somewhat discretionary to decide if a nutrigenomic 
product or service needs regulation because it concerns patient, 
not client data; or whether the information provided to the 
client or patient is medical advice, not wellness advice, that falls 
within the scope of practice of a regulated health care 
professional.91 
V. INNOVATION, UNCERTAINTY, REGULATION AND 
NUTRIGENOMICS 
Convergence in biotechnology innovation facilitates the 
leveraging of new biotechnology innovation, often at a 
surprisingly accelerated pace. Corresponding regulatory 
adaptation to new products and services is often warranted, but 
 90. See, e.g., David J.A. Jenkins et al., A Dietary Portfolio Approach to 
Cholesterol Reduction: Combined Effects of Plant Sterols, Vegetable Proteins, 
and Viscous Fibers in Hypercholesterolemia, 51 METABOLISM 1596, 1600–02 
(2002). 
 91. These issues are considered fully in CASTLE ET AL., supra note 22, at 
111–32. 
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obstacles lie in the path of regulatory initiatives. This is 
particularly the case when regulatory agencies are strongly 
“siloed,” which is to say they have a narrow mandate that is 
maintained with well-integrated vertically controlled policies 
and procedures, but lack horizontal collaborative capacity, 
policies or procedures that would enable inter-mural regulatory 
cooperation to a greater extent. In previous work on convergent 
biotechnology regulation, five obstacles besetting regulatory 
agencies have been identified.92 These are: the complexity of a 
problem that may escape the scope of the regulatory agency’s 
mandate and capacity; a regulatory culture in which a given 
agency is uncooperative with other agencies; a reactive, rather 
than proactive mode of the agency; an obsession with “sound 
science” to the point where it alone is believed to solve all 
aspects of regulatory problems; and finally, the desire to focus 
on domestic regulation only when international harmonization 
of standards might be equally important.93 
Overcoming these obstacles requires, at minimum, 
regulatory analysis to identify limits of existing regulation and 
to close gaps with new regulations. It might also be necessary to 
be quite innovative in the development of regulatory 
frameworks to address the challenges of new classes of product 
and services if the novelty, range and hazardousness of 
identified risks are outside the known and familiar scope of 
regulation. In short, science and technology innovation can drive 
regulatory innovation. Evidence of change, or the need for 
change, can be found in situations where there is demand for 
four types of regulatory innovation: new regulatory concepts and 
definitions; new regulatory processes; new regulatory 
structures; and new regulatory paradigms. A fifth and final 
source of innovation arises when the first four developments are 
synthesized into evolving, over-arching conceptions of 
governance and regulation.94 
Demands for regulatory change can easily outstrip the 
capacity of regulatory agencies to identify and respond to new 
issues. Sometimes it is the case that basic issues are not yet 
resolved and so a new regulatory regime cannot be imposed 
until the fact situation is resolved.  Take, for example, the role 
of the health practitioner, an issue which is relevant in 
 92. CASTLE ET AL., supra note 84 at 65–67. 
 93. Id. 
 94. Id. at 71. 
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nutrigenomics.  One option for addressing concerns about the 
advice given to clients and patients is to make sure that 
regulated health care professionals are involved in, or are the 
sole provider, of the advice. While appealing on the surface, 
health care practitioners do not have reassuring levels of 
appropriate training to address issues in nutrigenomics. 
Reviews of North American medical school curriculae indicate 
that genetics and genomics training are low priority for health 
care practitioners.95 In their daily practice, the training gap is 
reinforced because practitioners are more like than not to say 
that while genetics and genomics are important scientifically, 
they do not have immediate relevance and impact to clinical 
practice.96 In the absence of detailed knowledge, confidence in 
applications of genetics and genomics, and an obvious clinical 
need, health care practitioners do not view the future of genetics 
and genomics in clinical practice as positive, current 
knowledge.97 No health care practitioner field has “claimed” 
nutrigenomics as its territory, and so fundamental issues 
requiring public education are likely to remain touched by 
health care practitioners for the foreseeable future.98 In a 
situation such as this, a regulator cannot expect regulated 
professions to take up the regulatory slack, or to be effective 
resources to guide regulators in identifying issues. The opposite 
is true: regulators likely have more insight than professional 
groups when it comes to nutrigenomics because they are closer 
to the problems presented by rapid innovation, whereas 
professional groups are penultimate end users of 
commercialized technologies. 
Nutrigenomics can be regulated in the United States 
principally through the control of genetic tests.99 The two 
 95. See Alan E. Guttmacher, Mary E. Porteous & Joseph D. McInerney, 
Educating Health-Care Professionals About Genetics and Genomics, 8 NATURE 
REVIEWS: GENETICS 151, 154–55 (2007); Ann Silversides, The Wide Gap 
Between Genetic Research and Clinical Needs, 176 CAN. MED. ASS’N J. 315, 316 
(2007). 
 96. See Guttamacher, Porteous & McInerney, supra note 95, at 153–55. 
 97. David Castle, Clinical Challenges Posed by New Biotechnology, 79 
POST-GRADUATE MED. J. 65, 66 (2003). 
 98. See Stephanie Kurzenhäuser & Ralph Hertwig, How to Foster Citizens’ 
Statistical Reasoning: Implications for Genetic Counseling, 9 COMMUNITY 
GENETICS  197, 198–99 (2006). 
 99. For a full discussion of relevant U.S. regulations, and comparison with 
other jurisdictions, see Nola M. Ries,  Regulating Nutrigenetic Tests: An 
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applicable statues are the Clinical Laboratory Improvement 
Amendments (CLIA)100 and the Food, Drug, and Cosmetic Act 
(FDCA).101 CLIA certification of laboratories conducting genetic 
tests, which are regarded as “high complexity tests,” ensures 
that genetic tests meet standards for quality control and testing 
proficiency.102 The FDA also has authority to regulate genetic 
tests under the FDCA, particularly the sale of genetic tests kits, 
which are regulated as in vitro diagnostic devices (IVDs).103 The 
FDA decides which of three classes of medical device an IVD 
falls into, depending on the risk that it poses. In addition to 
CLIA and the FDCA, the Federal Trade Commission (FTC) 
protects consumers from deceptive commercial practices and 
false advertising.104 In this respect, the FTC ensures that tests 
that have been approved by the FDA are marketed with truthful 
advertising. 
The GAO report and the Senate Special Committee on 
Aging hearing held in Washington D.C. on July 27, 2006105 was 
intended to put pressure on the FDA to use existing regulations, 
and to develop new regulations, in order to protect consumers. 
The central claim of the GAO report is that there is no 
nutrigenomic-specific regulation that would protect consumers 
from maleficent private sector interests.106 Given the newness of 
the field, it should come as no surprise that tailor-made 
regulations have not been developed for this budding field. More 
importantly, direct-to-consumer nutrigenomic tests presently 
comprise a very small market, and so it is unlikely that 
nutrigenomic-specific regulations will be developed until the 
market grows significantly. The regulatory issue, then, is 
whether existing regulations meet the regulatory challenges 
posed by nutrigenomics.107 
Despite the gap in health care practitioner knowledge about 
International Comparative Analysis, 16 HEALTH L. REV. (forthcoming 2008). 
 100. Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 
U.S.C. § 263a (2000). 
 101. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301–399 (2000). 
 102. 42 U.S.C. § 263a(b) (2000). 
 103. 21 U.S.C. § 321(h) (2000). 
 104. 15 U.S.C. §§ 45, 52 (2000). 
 105. U. S. GOV’T ACCOUNTABILITY OFFICE, supra note 64; At Home DNA 
Tests: Marketing Scam or Medical Breakthrough?: Hearing Before the S. Spec. 
Comm. on Aging, 109th Cong. (2006). 
 106. U. S. GOV’T ACCOUNTABILITY OFFICE, supra note 64, at 22. 
 107. Whether the regulations are being enforced is a separate issue beyond 
the scope of this paper. For consideration of this issue, see Ries, supra note 99. 
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genetics and genomics discussed earlier, the FTC has noted that 
consumers might be taking tests for which they may wish to 
seek independent advice. To this end, the FTC has encouraged 
the public to speak with their physicians about at-home genetic 
tests.108 The FTC’s advice to the public regarding at-home 
genetic tests has a dual function. On the one hand, by issuing 
the advice to consumers, the FTC has taken action which is 
consistent with the FTC’s approach to the marketing of genetic 
tests. Second, the FTC does not over-reach its regulatory 
authority, since it generally receives guidance from the FDA 
about what would constitute appropriate claims for genetic test 
kit.109 
With respect to the adequacy of existing regulations, to say 
that there are no efforts to address the regulatory gaps 
associated with nutrigenomics misses some of the more 
interesting actions by the FDA. There are, for example, 
regulatory amendments that would extend powers to the FDA’s 
oversight of clinical laboratories.110 In addition, the FDA has 
issued two important guidance documents—public documents 
stating the FDA’s position on the correct interpretation of 
legislated regulation. 
In the first guidance document, the FDA attempts to bring 
regulatory clarity to the question of what counts as an analyte 
specific reagent (ASR) for commercial distribution and how it 
will be regulated. 111 This is an important guidance document, 
 108. FEDERAL TRADE COMMISSION, TALK TO YOUR DOCTOR OR HEALTHCARE 
PRACTITIONER ABOUT HOME GENETIC TESTS (2006), available at 
http://www.ftc.gov/opa/2006/07/fyi0650.shtm; FEDERAL TRADE COMMISSION, 
AT-HOME GENETIC TESTS: HEALTHY DOSE OF SKEPTICISM MAY BE THE BEST 
PRESCRIPTION (2006), available at http://www.ftc.gov/bcp/edu/pubs/consumer/ 
health/hea02.shtm. 
 109. Working Agreement Between the Federal Trade Commission and the 
Food and Drug Administration, 3 Trade Reg. Rep. (CCH) ¶ 9850.01 (1954) (as 
originally enacted). In 1971, the Agreement was amended to provide the FDA 
with explicit and primary authority over prescription drug advertising. 
Memorandum of Understanding, 36 Fed. Reg. 18,539, 4 Trade Reg. Rep. (CCH) 
¶ 9851 (Sept. 16, 1971). 
 110. FDA Guidance Document: “Recommendations for Clinical Laboratory 
Improvement Amendments of 1988 (CLIA) Waiver Applications for 
Manufacturers of In Vitro Diagnostic Devices,” 73 Fed. Reg. 5,574 (Jan. 30, 
2008). 
 111. Guidance for Industry and FDA Staff Regarding Commercially 
Distributed Analyte Specific Reagents 72 Fed. Reg. 52,568 (Sept. 14, 2007). 
Analyte Specific Reagents (ASRs) are defined as “antibodies, both polyclonal 
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because ASRs are necessary components of any genetic test kit, 
or any so-called “home brew” test which is offered as a 
laboratory service rather than a test kit. Under the broad 
definition provided by the FDA for ASRs in this guidance 
document, many of the reagents used in DNA typing will be 
controlled by FDA regulations, meaning that nutrigenomic tests 
offered either as a genetic test kit or a home-brew test would 
generally be subject to regulations subsequent to this draft 
guidance. The major implication for nutrigenomics is that the 
use of some reagents can have significant implications for the 
medical device classification of a test. 
In the draft guidance, the FDA also made a direct 
connection between tests likely to use ASRs and some kind of 
analytical step, potentially an algorithm that performs a 
calculation based on the results of an ASR-based test.112 The 
conjunction of these two steps, in an in vitro diagnostic, multi-
variate index assay (IVDMIA) would be regulated together 
because the two parts are “inextricably linked in obtaining the 
patient-specific result.”113  This means that the diagnostic assay 
and the algorithm must be considered together, which de facto 
extends the FDA’s regulatory reach to the algorithm, which was 
not previously regulated. The guidance document has 
implications for how nutrigenomic tests will be classified and 
and monoclonal, specific receptor proteins, ligands, nucleic acid sequences, and 
similar reagents which, through specific binding or chemical reactions with 
substances in a specimen, are intended for use in a diagnostic application for 
identification and quantification of an individual chemical substance or ligand 
in biological specimens.” Id. (citing 21 CFR 864.4020(a) (2006)). 
 112. Id. 
 113. OFFICE OF IN VITRO DIAGNOSTIC DEVICE EVALUATION & SAFETY, U.S. 
DEP’T OF HEALTH AND HUMAN SERVICES, GUIDANCE DOCUMENT 1610, DRAFT 
GUIDANCE FOR INDUSTRY, CLINICAL LABORATORIES AND FDA STAFF: IN VITRO 
DIAGNOSTIC MULTIVARIATE INDEX ASSAYS 3 (2006), available at 
http://www.fda.gov/OHRMS/DOCKETS/98fr/06d-0347-gdl0001.pdf. The 
document reads: 
[e]ven if a laboratory or other IVDMIA manufacturer physically or 
procedurally separates the analyte measurement portion of the test 
system (i.e., the first step described above) from the calculation portion 
of the test system (i.e., the second step described above), the two parts 
are inextricably linked in obtaining the patient-specific result that is 
reported in the third step. A physician could not use the variables 
derived in step one for the intended use of the test absent the 
algorithm that integrates them to calculate the patient-specific result. 
Likewise, the physician could not use the algorithm without the assay 
portion of the test system (step one) as specified by the manufacturer. 
Use of the complete test system—assay and algorithm—is required to 
obtain a meaningful test result. Id. 
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regulated as medical devices if they are in fact based on an 
algorithm-supported calculation which is interpreted as part of 
an IVDMIA. 
VI. CONCLUSION 
The controversy surrounding the regulation of 
nutrigenomics is partly attributable to the newness of the field. 
The promise of nutrigenomics will be fulfilled only if the science 
and technology is demonstrably useful and translated into 
products and services of use to patients and consumers. The 
availability of direct-to-consumer nutrigenomic tests has been a 
lightning rod for scrutiny of these offerings and for the science 
as a whole. Amidst legitimate questions about the strength of 
the science and utility of its applications, there has been 
increasing scrutiny of the regulatory capacity needed to ensure 
public safety. Because nutrigenomics is a convergent science 
and technology, it is to be expected that limits of regulations 
and gaps between regulations will be exposed, particularly with 
public offerings of nutrigenomics. Yet this chain of events, far 
from supporting calls for nutrigenomic-specific regulations, 
points to a more general conclusion about innovation, 
convergent technologies and regulation. 
There cannot be a law for everything one might wish to 
regulate, but there are viable, non-statutory means for 
regulating a field like nutrigenomics. Given that the field is 
rapidly changing and regulatory issues are still being evaluated, 
guidance documents give regulators non-statutory tools by 
which they can regulate the field. The ASR guidance document 
and the IVDMIA draft guidance document address one of the 
central issues in nutrigenomics—the regulation of genetic tests 
in the commercial environment. Of course, there remain the 
issues about health claims and associated supplement 
regulation, and these issues will surely be taken up in the 
future. In the meantime, it is worth reflecting on the fact that 
regulatory innovation requires time, thoughtful consideration of 
the issues and options, as well as intensive and extensive 
resources.114 
 114. See generally NEW MODES OF GOVERNANCE IN THE GLOBAL SYSTEM 
(Mathias Koenig-Archibugi & Michael Zürn eds., 2006); REGULATORY 
INNOVATION: A COMPARATIVE ANALYSIS (Julia Black, Martin Lodge & Mark 
Thatcher eds., 2005). 
